Journal
CLINICA CHIMICA ACTA
Volume 509, Issue -, Pages 167-171Publisher
ELSEVIER
DOI: 10.1016/j.cca.2020.06.006
Keywords
Intestinal microbiota; Farnesoid X receptor; Metabolic disease; Bile salt hydrolase; Metformin
Categories
Funding
- National Natural Science Foundation of China [81670424]
- Key Scientific Research Fund of Hunan Provincial Education Department [15A166]
- Scientific Research Fund of Hunan Provincial Health and Family Planning Commission [B2016087]
- Hunan College Students Innovation and Entrepreneurship Training Program [S20191055035, X2019131]
- project of State Administration of Work Safety [hunan-0013-2016AQ]
Ask authors/readers for more resources
Studies have demonstrated that intestinal microbiota is associated with various metabolic diseases including obesity, nonalcoholic fatty liver, and insulin resistance. Farnesoid X receptor (FXR), also known as the bile acid receptor, belongs to the nuclear receptor superfamily, which is involved in the regulation of bile acid, glucose, and lipid metabolism. Researchers have found that intestinal microbiota can regulate FXR activity by affecting bile acid composition, and then regulate the balance of in vivo metabolism. The intestinal microbiota-FXR axis may be an ideal drug target for metabolic diseases. This review summarizes the latest research on the intestinal microbiota /FXR axis, hoping to provide a theoretical basis for further research and clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available